Added to YB: 2026-10-09
Pitch date: 2026-10-06
SCTX [neutral]
Scribe Therapeutics Inc.
+29.99%
current return
Author Info
Two Natural Capital writes about markets, particularly focused on life sciences/biotech. Sign up for the newsletter.
Company Info
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Market Cap
$309.2M
Pitch Price
$15.94
Price Target
N/A
Dividend
N/A
EV/EBITDA
-16.68
P/E
-1.24
EV/Sales
12.91
Sector
Biotechnology
Category
growth
Scribe Therapeutics: The World of Epigenetic Editing $sctx
SCTX (deep dive): Scribe’s epigenetic PCSK9 therapy offers one-time convenience without altering DNA, but uptake is difficult to underwrite: STX-1150 lowered LDL-C 51-68% in nonhuman primates, insufficient for the most severe patients, while off-target methylation may carry serious and not clearly reversible risks. Initial clinical data is expected in 1H27, with cash through 1H29.
Read full article (7 min)